Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Joan Montero, Jason Stephansky, Tianyu Cai, et al.
Cancer Discovery (2016) Vol. 7, Iss. 2, pp. 156-164
Open Access | Times Cited: 184

Showing 26-50 of 184 citing articles:

Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target
Maria Rosaria Sapienza, Francesco Abate, Federica Melle, et al.
Haematologica (2018) Vol. 104, Iss. 4, pp. 729-737
Open Access | Times Cited: 69
Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
Bora Lim, Yoshimi Endo Greer, Stanley Lipkowitz, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1087-1087
Open Access | Times Cited: 68
Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies
Joan Montero, Cécile Gstalder, Daniel J. Kim, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 63
Cell death pathologies: targeting death pathways and the immune system for cancer therapy
Francesca Pentimalli, Sandro Grelli, Nicola Di Daniele, et al.
Genes and Immunity (2018) Vol. 20, Iss. 7, pp. 539-554
Open Access | Times Cited: 61
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Marina Konopleva
Blood Advances (2020) Vol. 4, Iss. 16, pp. 4020-4027
Open Access | Times Cited: 58
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
Blood Advances (2020) Vol. 4, Iss. 19, pp. 4838-4848
Open Access | Times Cited: 58
Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Katsuhiro Togami, Sun Sook Chung, Vikas Madan, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 522-541
Open Access | Times Cited: 46
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
Tianyu Cai, Agnès Gouble, Kathryn L. Black, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 31
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia‐Manero, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3027-3035
Open Access | Times Cited: 30
Plasmacytoid dendritic cell neoplasms
Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, et al.
Blood Research (2023) Vol. 58, Iss. S1, pp. S90-S95
Open Access | Times Cited: 19
Blastic Plasmacytoid Dendritic Cell Neoplasm
Joseph D. Khoury
Current Hematologic Malignancy Reports (2018) Vol. 13, Iss. 6, pp. 477-483
Closed Access | Times Cited: 53
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, et al.
Blood (2018) Vol. 133, Iss. 6, pp. 566-575
Open Access | Times Cited: 52
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm
Mounzer Agha, Sara A. Monaghan, Steven H. Swerdlow
New England Journal of Medicine (2018) Vol. 379, Iss. 15, pp. 1479-1481
Closed Access | Times Cited: 47
Blastic Plasmacytoid Dendritic Cell Neoplasm–Current Insights
Sangeetha Venugopal, Selena Zhou, Siraj M. El Jamal, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 9, pp. 545-554
Closed Access | Times Cited: 47
Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm
Sho Kubota, Kenji Tokunaga, Tomohiro Umezu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 45
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, et al.
Blood (2021) Vol. 138, Iss. 15, pp. 1373-1377
Open Access | Times Cited: 41
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
Serena Zanotta, Domenico Galati
(2024)
Open Access | Times Cited: 5
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies
Shefali Mehra, Justin Taylor
Cells (2024) Vol. 13, Iss. 3, pp. 243-243
Open Access | Times Cited: 5
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases
Weili Sun, Huaying Liu, Young Kim, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, et al.
Expert Opinion on Drug Discovery (2017) Vol. 12, Iss. 10, pp. 1031-1040
Open Access | Times Cited: 43
Plasmacytoid dendritic cell proliferations and neoplasms involving the bone marrow
Alexandar Tzankov, Konnie M. Hebeda, Markus Kremer, et al.
Annals of Hematology (2017) Vol. 96, Iss. 5, pp. 765-777
Closed Access | Times Cited: 41
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Felix Seyfried, Salih Demir, Rebecca Louise Hörl, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 8
Open Access | Times Cited: 39
Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment
Kendra Sweet
Current Opinion in Hematology (2020) Vol. 27, Iss. 2, pp. 103-107
Closed Access | Times Cited: 37
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Hannah C. Beird, Maliha Khan, Rui Wang, et al.
Blood Cancer Journal (2019) Vol. 9, Iss. 12
Open Access | Times Cited: 36

Scroll to top